NICE gives AF patients more options with Sanofi-Aventis's Multaq
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for Health and Clinical Excellence in the UK, yesterday published final guidance recommending Sanofi-Aventis's Multaq (dronedarone) as a second-line treatment for patients with atrial fibrillation.